



OPEN ACCESS

APPROVED BY

Giuseppe Giaccone,
Vice President Global Development,
United States

*CORRESPONDENCE

Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 13 November 2023

ACCEPTED 13 November 2023

PUBLISHED 07 December 2023

CITATION

Frontiers Editorial Office (2023) Retraction:
Emodin interferes with AKT1-mediated
DNA damage and decreases resistance of
breast cancer cells to doxorubicin.
Front. Oncol. 13:1337635.
doi: 10.3389/fonc.2023.1337635

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Emodin interferes with AKT1-mediated DNA damage and decreases
resistance of breast cancer cells to doxorubicin](#)

by Li B, Zhao X, Zhang L and Cheng W (2021) *Front. Oncol.* 10:588533. doi: 10.3389/fonc.2020.588533

The journal retracts the February 2021 article cited above.

Following publication, the authors contacted the Editorial Office to request the retraction of the cited article, stating concerns regarding the use of an incorrect dataset in the published article. It was confirmed by the authors when they tried to repeat their experiments unsuccessfully. The findings and conclusions reported in the article are no longer supported by the data. An investigation was conducted in accordance with Frontiers' policies that confirmed this; therefore, the article is retracted.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.